Invivyd surged after Merck’s Cidara acquisition, but the read-through for IVVD is limited due to key differences. Learn why ...
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback